Apixaban: a new player in the anticoagulant class.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Development

Background:

• Apixaban is an anticoagulant medication developed as a joint venture by Pfizer and Bristol-Myers Squibb.
• It functions as a selective coagulation factor Xa inhibitor.
• Apixaban received E.U. approval in 2011 for preventing venous thromboembolic events post-hip or knee replacement.

Purpose of the Study:

• To provide a comprehensive review of apixaban, focusing on medicinal chemistry aspects.
• To compare apixaban with other factor Xa inhibitors and existing anticoagulants.
• To detail apixaban's molecular properties, clinical efficacy, and safety profile.

Main Methods:

• Review of existing literature on apixaban and related factor Xa inhibitors.
• Analysis of clinical trial data comparing apixaban to warfarin, aspirin, and enoxaparin.
• Examination of X-ray crystal structure data to understand molecular interactions.
• Assessment of pharmacokinetic and pharmacodynamic properties.

Main Results:

• Apixaban demonstrated a >50% reduction in stroke or systemic embolism risk compared to aspirin in atrial fibrillation patients.
• Apixaban showed superiority to enoxaparin in preventing thrombosis after hip replacement surgery, with comparable bleeding rates.
• Apixaban is a potent and selective factor Xa inhibitor with a Ki of 0.8 nM.
• Structural studies reveal specific molecular interactions within the factor Xa active site.

Conclusions:

• Apixaban represents a significant advancement in anticoagulant therapy.
• Its efficacy and safety profile suggest it is a competitive alternative to existing treatments like warfarin.
• Further emphasis on medicinal chemistry aspects aids in understanding its therapeutic advantages.